Aim: The aim of this study is to highlight the effectiveness of music therapy in Alzheimer's Disease (AD) and their caregivers. Methods: The biennial 2019 to 2020, 32 patients, with AD (ICD-10), were examined, by a research group composed by a Neurologist, a GP and a Music-psychotherapist. All patients were under pharmaceutical care. The patients' medical record and musical profile was assessed. The answers were provided by the patients themselves or by their tutors. Then, personal or family sessions were organized with the participation of musical instruments. The patients staging and evaluation were made through MMSE. The test was repeated every six months under the Neurologist's supervision. Finally, 31 totally patients succeeded to complete our intervention and to be estimated. Results: The duration of follow-up of the patients was 30 months. At the beginning and end of the sessions we obtained the following data: In a total of 32 patients with AD, initially 3 patients (9.37%) had Mild AD, 19 patients (59.37%) had Moderate AD, 10 patients (31.25%) severe AD, based on the MMSE evaluation. After 30 months, 11 patients had Mild AD (35.48%), number resulting from the music benefit of cognitive function in patients with moderate AD. 15 patients with Moderate AD (48.38%) were observed, out of the initial 19 (59.37%) patients with Moderate AD, a number attributed to the sum of patients who improved from severe AD and those who were transferred, benefiting from treatment, from Moderate AD disease to Mild AD. Finally 5 patients with severe AD disease were evaluated (16.12%), while before the treatment we had 10 patients (31.25%) with severe AD. Conclusions: Music therapy is a tool to increase the life quality of the participants. The results expected in the treatment of AD are obtained by means of good collaboration among the research team.

COVID-19 disease constitutes a significant threat to human existence worldwide due to the increased transmissibility, morbidity and mortality caused by the still unknown SARS-COV2 virus. A critical issue is the lack of effectiveness of drug options. In our research, a literature review, we explore the role of bioactive lipids and statins can play, as a main or adjunctive treatment in the COVID-19. We reviewed 150 articles in the Databases (PubMed/MEDLINE, Google Scholar, Embassy and Cochrane) relatives of the use of bioactive lipids and statins in severe COVID-19 disease and we selected 117 articles that fit with our research question. So, our research constitutes a bibliography review of 117 articles, finally. The administration of exogenous bioactive lipids (BALs), Omega 3 EPA, DHA supplements induces the suppression of pro-inflammatory cytokines, the prevention of cytokine storm and enhancing the therapeutic benefit by accelerating recovery. Therefore, they potentially reduce the need for ICU hospitalization and the number of intensive care unit days of stay, accelerating recovery thus also numerically reducing critical cases. The possible harms of lipids should be considered. There are positive and negative effects regarding the use of statins. According to the literature, Statins offer beneficial effects on COVID-19 disease. For de novo statin use in COVID-19 patients, the Benefit/Risk ratio should be taken into account. In conclusion, although lipids and statins seem to benefit patients with severe COVID-19 disease, nevertheless, more double blind randomized studies are needed to determine their safety and efficacy profile.